[go: up one dir, main page]

WO1999005310A1 - Milieu de germination de spores - Google Patents

Milieu de germination de spores Download PDF

Info

Publication number
WO1999005310A1
WO1999005310A1 PCT/US1998/015612 US9815612W WO9905310A1 WO 1999005310 A1 WO1999005310 A1 WO 1999005310A1 US 9815612 W US9815612 W US 9815612W WO 9905310 A1 WO9905310 A1 WO 9905310A1
Authority
WO
WIPO (PCT)
Prior art keywords
effector
germinant
spore germination
germination medium
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/015612
Other languages
English (en)
Inventor
Kestutis J. Tautvydas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Priority to JP2000504279A priority Critical patent/JP2001511356A/ja
Priority to AU85970/98A priority patent/AU8597098A/en
Publication of WO1999005310A1 publication Critical patent/WO1999005310A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/22—Testing for sterility conditions

Definitions

  • the invention relates to microbial spore germination media.
  • the invention relates to germination media that affect the rate of spore germination.
  • the invention further relates to germination media that affect the relationship between spore germination rates and spore survival after exposing spores to a sterilant.
  • a spore is a rigid structure with no detectable metabolic activity.
  • the general spore structure includes an outer exosporium, a spore coat, a spore cortex, an inner membrane and finally a spore core cell .
  • Endospores are significantly more resistant to environmental fluctuations in pH, temperature, humidity and radiation than are vegetative cells. Foster & Johnstone, Molecular Microbiol., 4 (1) :137-41 (1990) .
  • spores contain mechanisms that trigger germination under certain circumstances.
  • the germination process consists of a series of degradative steps that break down the spore coat and spore cortex allowing water and nutrients to enter the spore core cell. Following germination, metabolic activity is reactivated and outgrowth of a new vegetative cell occurs .
  • Germination and subsequent outgrowth are distinct but related processes. That is, even though a spore germinates it might not complete the outgrowth process. Outgrowth of a new vegetative cell, however, cannot occur unless the spore germinates.
  • the mechanisms that trigger spore germination are not fully understood. Depending on the species, germination can be triggered by exposing the spores to germinants or certain environmental stimuli or both. Johnstone, K. , J. APPI . Bac ⁇ Symposium Supp .. 76:17S-24S (1994) .
  • Bacillus subtilis contained two germination pathways. In one pathway, -Ala alone was capable of triggering spore germination (GS-I) . Wax & Freese, J. Bac ⁇ , 95(2):433-38 (1968) . The other pathway required a combination of L- Asn or L-Gln plus glucose, fructose and potassium ions to trigger spore germination (GS-II) . Wax & Freese, J. Bac .. 95(2):433-38 (1968). Further research conducted with Bacillus subtilis has identified a third germination system.
  • This third germination system is also triggered by a combination of L-Ala, glucose, fructose, and potassium ions (GS-III) , McCann et al., ⁇ Letters Appl . Bact . , 23:290-93 (1996). Even with the identification of multiple germination systems, however, the identity of the receptors involved and the interactions between the receptors and germination active components remain unclear. See Foster and Johnstone, Molecular Microbiol . , 4:137 (1990); Johnstone, K, J. Appl . Bact_. Symposium Suppl. , 76:17S-24S (1994); Moir et al . , J. Appl. Bact . Symposium SUPPI .. 76:9S-16S (1994).
  • the present invention involves the discovery that when certain germinants and effectors are combined in a germination medium, they will act synergistically to alter microbial spore germination rates. Further, optimization of the germinant and effector concentrations alters the dose-response relationship between the rate of spore germination and sterilant exposure time, which facilitates rapid evaluation of sterilization efficacy.
  • a spore germination medium is any medium that induces a measurable amount of spore germination.
  • An effector is a compound that, when added to a germination medium, acts synergistically with a germinant to produce an increase in the RV of spore germination and a decrease in the apparent K Too for the germinant triggering spore germination, compared to the same germination medium lacking the effector.
  • the invention is useful for germinating spores including without limitation Bacillus subtilis, Bacillus circulans, Bacillus pu ilus, Clostridiu perfringe s, Clostridium sporogenes and Bacillus stearother ophilus spores.
  • the invention provides a spore germination medium containing a phosphate buffer at a concentration from about o.l molar to about 0.2 molar and synergistic amounts of a germinant and an effector.
  • This spore germination medium can be optimized for the LRV response of microbial spores, that have been exposed to a sterilization process, by, for example, adjusting the phosphate buffer concentration to about 0.15 molar.
  • the spore germination medium can also be optimized for particular germination systems including the GS-II system.
  • the invention provides a spore germination medium containing a phosphate buffer at a concentration from about 0.1 molar to about 0.2 molar, synergistic amounts of a germinant and an effector, sodium chloride, potassium chloride, glucose and fructose.
  • the germination media disclosed herein can be useful for determining the effectiveness of a sterilization process by following the steps of exposing microbial spores to a sterilant, contacting the spores with a spore germination medium, and calculating the LRV of spore germination to determine the effectiveness of the sterilization process
  • the invention provides a biological indicator for indicating the effectiveness of a sterilization process.
  • the biological indicator contains a germination medium having synergistic amounts of a germinant and an effector wherein the medium produces a sterilant exposure time/LRV response curve slope greater than about 0.016.
  • the medium contained within the biological indicator may also contain a phosphate buffer at a concentration from about 0.1 molar to about 0.2 molar.
  • the invention provides a biological indicator that includes a first container containing dried microbial spores that is further adapted to exposing microbial spores to a sterilant and computing an LRV for germinating spores.
  • a biological indicator also contains a second container adapted for storing a germination medium that contains a phosphate buffer at a concentration from about 0.1 molar to about 0.2 molar, and synergistic amounts of a germinant and an effector.
  • the invention provides a method for identifying an effector by 1) contacting spores with a germination medium containing a compound with unknown effector properties and lacking a germinant, and then computing an LRV; 2) contacting spores with a germination medium containing the germinant and lacking the compound with unknown effector properties, and computing an LRV; 3) contacting spores with a germination medium containing the germinant and the compound with unknown effector properties, and computing an LRV; and 4) calculating an S value to determine the effectiveness of the compound with unknown effector properties.
  • the germinant may include an L-amino acid or an operable derivative thereof at concentrations from about 0.0003 mg/ml to about 30 mg/ml, preferably from about 0.001 mg/ml to about 0.01 mg/ml or from about 0.1 mg/ml to about 1.0 mg/ml.
  • Useful germinants include, but are not limited to, alanine, ⁇ -amino butyric acid, norvaline, cysteine, valine, isoleucine, ⁇ -alanine, serine, homoserine, leucine, methionine, allothreonine, and threonine .
  • the effector may include a D-amino acid, an L-amino acid, or an operable derivative thereof at concentrations from about 0.1 mg/ml to about 20 mg/ml, preferably from about 0.1 mg/ml to about 10 mg/ml, more preferably from about 3 mg/ml to about 8 mg/ml .
  • Useful effectors include, but are not limited to, asparagine, glutamine, homoserine, allothreonine, threonine, 4- acetamidobutyric acid, histidine, serine, 2- acetamidoacetic acid, and 6-acetamidohexanoic acid.
  • the invention is practical for use with a variety of sterilant sources including ethylene oxide, steam, radiation, heat, sodium hypochlorite, polyvinylpyrrolidone-iodine, sodium dichlorocyanurate, low temperature steam-formaldehyde, glutaraldehyde, hydrogen peroxide, hydrogen peroxide plasma, peracetic acid and mixtures thereof.
  • sterilant sources including ethylene oxide, steam, radiation, heat, sodium hypochlorite, polyvinylpyrrolidone-iodine, sodium dichlorocyanurate, low temperature steam-formaldehyde, glutaraldehyde, hydrogen peroxide, hydrogen peroxide plasma, peracetic acid and mixtures thereof.
  • sterilant sources including ethylene oxide, steam, radiation, heat, sodium hypochlorite, polyvinylpyrrolidone-iodine, sodium dichlorocyanurate, low temperature steam-formaldehyde, glutaraldehyde, hydrogen peroxide
  • FIG. 1 is a duplication of FIG. 1 of PCT International Publication WO 95/21936 and is a graph that depicts the absorbance at 480 nm versus time for a typical germinating suspension of Bacillus subtilis spores as described herein.
  • FIG. 2 is a duplication of FIG. 3 of PCT International Publication WO 95/21936 and is a graph that depicts the survival curve for Bacillus subtilis spores exposed to ethylene oxide having a D value of 2.7 minutes and an observed LRV curve for Bacillus subtilis spores.
  • the present invention involves the discovery that certain germinants and effectors, when combined in a germination medium (GM) , interact synergistically to alter microbial spore gemination rates. Further, optimization of germinant and effector concentrations alters the sterilant exposure time/germination response relationship, which facilitates rapid evaluation of a sterilization process.
  • GM germination medium
  • base germination medium is defined as a medium or solution that does not trigger spore germination by itself.
  • the present inventor has unexpectedly discovered that GM-base solutions further containing commercially available lots of L-Gln or L-Asn do not trigger Bacillus subtilis spore germination in a consistent manner. Some lots trigger germination (active lots) while other lots do not trigger germination (inactive lots) . The inventor has further discovered that substantially pure samples of L-Asn and L-Gln, when added to a GM-base solution, do not trigger spore germination to a significant extent.
  • L-Asn, L-Gln and certain other compounds interact synergistically with germinants to increase spore germination rates.
  • L-Asn, L-Gln and certain other compounds function as "effectors" that promote spore germination triggered by L-Ala or other germinants through the GS-II mechanism.
  • Such a discovery is useful in the general area of biological indicators. Germination media containing germinants and effectors and methods for using the media are disclosed and claimed herein.
  • Biological indicators and methods for producing biological indicators are known. Illustrative examples of biological indicators can be found in United States Patent NOS. 5,073,488, 3,661,717, 4,839,291, 4,741,437, and 4,416,984. Briefly, suitable biological indicators would allow access of a sterilant to the spores and would be adapted to contain a germination medium. Additionally, if the germination rate is determined spectrophotometrically, preferred biological indicators would be adapted to facilitate measuring the LRV of spore germination. A variety of containers made from quartz glass or polymeric materials such as poly (methylmethacrylate) or polystyrene, may be used to construct such a biological indicator.
  • spore forming bacteria include Bacillus subtilis, Bacillus circulans, Bacillus pumilus, Clostridium perfringens, Clostridium sporogenes, Bacillus cereus and Bacillus stearothermophilus .
  • a preferred bacterium is Bacillus subtilis .
  • Bacillus subtilis spores such as American Type Culture Collection (ATCC) accession no. 9372 can be used at concentrations ranging from about 0.5 x 10 8 spores/ml to about 3 x 10 8 spores/ml.
  • ATCC American Type Culture Collection
  • spore suspensions used in germination reactions contained about 1.2 x 10 8 viable spores per 1.2 ml of GM or GM-base solution. This concentration of Bacillus subtilis spores corresponds to an initial absorbance between about 0.45-0.50 absorbance units at 480 nm (Abs 480 ) measured in a 1 cm path length clear polymethacrylate cuvette.
  • Any spectrophotometer equipped with a temperature-controlled cuvette holder can be used to determine spore concentrations and/or spore germination kinetics.
  • the experiments described herein were performed at 37°C in a Varian/Cary 1 UV/visible spectrophotometer equipped with a temperature control unit and a software package used to calculate slopes and other kinetic parameters (version 13) .
  • spores for use in a GM are known.
  • the spores used herein were heat activated.
  • Spores can be heat activated by any acceptable method.
  • An illustrative example of heat activating Bacillus subtilis spores is heating an aqueous suspension of spores at about 47°C for four hours.
  • Another acceptable method for heat activating spores is to dry the spores onto a suitable carrier material at about 47°C for four hours. Heat activated spores are stable and will remain heat activated for an extended period of time, e.g., months.
  • the spores can be unpurified or purified.
  • Unpurified spores include spores harvested by conventional methods from bacterial cultures induced to sporulate by the appropriate stimuli. Unpurified spores often contain agar and/or cellular debris mixed in with the spores. Unpurified spores may be further purified by known methods. For example, to remove bits of agar, denatured nucleoproteins and other debris, spores can be resuspended in sterile deionized H 2 0, which does not trigger germination. The suspension is then filtered through a Whatman GF/D glass fiber filter (2.7 ⁇ m retention) . After filtration, the spore suspension is considered purified.
  • Purified spores in aqueous solutions can be further separated into heavy and light spores by differential centrifugation. Heavy spores pellet after centrifugation for 12 to 15 minutes at 2,000 x g, whereas the light spores remain in suspension. Light spores can be pelleted by centrifuging the supernatant remaining after pelleting the heavy spores for 30 minutes at 2,000 x g. Purification does not alter spore viability.
  • Purified spores can be stored as an aqueous suspension or dried.
  • Useful wavelengths of light for measuring changes in absorbance range from about 400 nm to about 700 nm, preferably about 460 nm to about 560 nm, and more preferably about 480 nm to about 520 nm. At these wavelengths, the absorbance per spore concentration is highest and the change in absorbance observed for germinating spores is still measurable. As the wavelength increases from 300 nm to 900 nm, the spore suspension's initial absorbance decreases asymptotically (more than 30% from 480 nm to 600 nm) , but the change in absorbance due to germination of the spores increases by less than 10%. Methods to observe spore germination are known and include methods disclosed in PCT International Publication WO 95/21936, which is hereby incorporated by reference .
  • Spore germination rates can be calculated from a plot of the absorbance of a germinating spore suspension versus time (germination kinetics curve) .
  • the observed spore germination rate is a function of the number of spores that germinate per unit time, which is affected by both the number of spores germinating and the time needed for each spore to germinate.
  • FIG. 1 illustrates a typical germinating suspension of Bacillus subtilis spores observed at 480 nm (Abs 480 ) .
  • Abs 480 Bacillus subtilis spores observed at 480 nm
  • the linear reaction velocity (LRV) is the maximum observed spore germination rate for a given suspension of spores.
  • the LRV is represented by the absolute value of the slope of the descending linear portion of the germination kinetics curve following the lag period. As such, even though a descending line has a negative slope, the slope is reported as a positive number. Therefore, as used herein, germinants and effectors reference to an "increase" in the slope of the LRV actually refers to a slope that is more negative.
  • the LRV occurred within the first 15 minutes after initiating spore germination.
  • Data points used to compute an LRV were typically taken between 2 and 10 minutes following the initiation of a spore germination reaction.
  • the length of the lag period can vary depending on, for example, the condition of the spores and the germination medium used. Nevertheless, the linear portion of the kinetics curve will be apparent from the germination kinetics curve. For example, the LRV in FIG. 1 occurred between 5 and 10 minutes .
  • Germinants trigger germination by binding to specific protein receptors found on or in the dormant spore. In this way, germinants are activators of the proteins that initiate enzymatic reactions resulting in spore germination. It is generally understood, however, that germinants are neither consumed nor altered during the germination process. Even so, the LRV plotted against germinant concentration obeys Michaelis-Menten steady state kinetics equation. Accordingly, the LRV is directly proportional to the germinant concentration and obeys saturation kinetics principles with respect to the germinant concentration. See IVoese et al . , J. Bact. Vol. 761:578-588 (1958) . Thus, the K bulk for a germinant can be determined.
  • the K guest is the germinant concentration that produces % maximal LRV.
  • the K bulk in such cases can be treated as an apparent dissociation or binding constant .
  • the K tract values reported herein were computed using the computer program "Enzyme Kinetics" (Trinity Software Version 1.5) .
  • the K tract values were derived from a Lineweaver-Burk (double reciprocal) plot of the LRV versus germinant concentration.
  • the invention provides a three-step method for identifying useful germinants and/or effectors.
  • the germination triggering characteristics of a compound having unknown germination properties can be identified by computing an LRV for spores germinated in a GM-base solution containing the unknown compound and lacking any known germinants. This initial experiment is repeated at a series of concentrations for the unknown compound. If the unknown compound triggers germination, the data can be used to compute a K ⁇ , for the unknown compound. Compounds that trigger germination are classified as germinants. It is to be understood, however, that the compound can be further classified as a good or poor germinant. An illustrative example of a good germinant is L-Ala. Illustrative examples of poor germinants are L-Met and L-ornithine.
  • the effector characteristics of the compound with unknown effector properties can be evaluated.
  • LRVs are computed for spores germinated in a GM containing both the unknown compound and a known germinant. If the unknown compound is an effector for the known germinant, the LRV response will be synergistic. For Bacillus subtilis spores, the known germinant is typically L-Ala or L-Val .
  • the germinant concentration should be sufficiently low such that, in the absence of the unknown compound, the germinant concentration should be sufficiently below the maximum LRV response for the germinant alone so as to allow detection of an increase in LRV due to the presence of the effector molecule.
  • the LRV for the known germinant in the absence of the unknown compound may be determined.
  • L-Ala was used at a concentration that produced an LRV of about 1/2 max LRV.
  • the effector characteristics are measured at multiple concentrations, which facilitates identifying compounds that are effectors over only a limited concentration range and facilitates evaluating the dose- response relationship between an effector and germinant. Equations 1 or 2 can be used to identify synergy between the unknown compound and the known germinant .
  • LRV E Equation 1 requires computing three independent LRVs .
  • LRV EG is the LRV for a GM containing both the known germinant and the unknown compound.
  • LRV G is the LRV for the GM containing only the known germinant at the same concentration used to compute the LRV EG .
  • LRV E is the LRV for the GM containing only the unknown compound at the same concentration used to compute the LRV EG .
  • the unknown compound is considered an effector "candidate" when S x > 1.1 because a true effector will also cause a concomitant decrease in the Knd of the known germinant (discussed below) .
  • compounds that are antagonistic may produce negative S x values.
  • Equation 2 is preferred because under the conditions disclosed herein the resulting S values are typically positive.
  • equation 2 the LRV E , LRV G , and LRV EG are defined the same as in equation 1.
  • the unknown compound is considered an effector candidate if S 2 > 1.1.
  • the unknown is considered a marginal effector candidate if 1 ⁇ S 2 ⁇ 1.15.
  • the unknown is not an effector if S 2 is about equal to or less than 1.
  • S x corresponds to an S value computed using equation 1
  • S 2 corresponds to an S value computed using equation 2.
  • a third step can be used to determine if an effector candidate is a true effector. This step is typically also used to determine the degree of activity for an effector or marginal effector.
  • GMs containing a saturating concentration of the unknown compound are prepared. Saturating concentrations of the unknown compound can be computed from step two . LRVs are then computed for spores germinated in GMs containing a saturating concentration of the unknown compound and further containing increasing concentrations of the known germinant. Using a double reciprocal plot, the K shadow for the germinant in the presence of the effector can be determined. Effector candidates are true effectors when the inclusion of the effector candidate in a GM causes a decrease in the apparent K shadow for the germinant compared to the Kache for the germinant triggering germination in the absence of the effector candidate.
  • the degree of synergy between any effector or unknown compound and the known germinant can be estimated by computing a K grasp ratio.
  • the K grasp ratio is the K grasp computed for the germinant alone divided by the K ⁇ computed for the germinant in the presence of the effector or unknown compound.
  • a compound that acts as an effector will result in a K grasp ratio > 1.
  • tested compounds that act as germinants and/or effectors are synergistic when the LRV computed for spores germinated in a GM-base solution further containing two or more of the tested compounds is greater than the sum of the LRVs computed for spores germinated in the GM-base solution further containing each of the tested compounds individually.
  • the LRV for the GM-base further containing two or more tested compounds together is equal to the sum of the LRVs measured for each tested compound alone, the LRV response is additive.
  • the LRV response is antagonistic, i.e., competitive. Spore Sensitivity to Sterilant Exposure
  • Microorganism or spore death caused by an external factor such as ethylene oxide (EtO) is described best using first order kinetics since the decrease in the number of surviving organisms is logarithmic. Pflug and Holcomb, "Principles of the thermal destruction of microorganisms", Disinfection, Sterilization, and Preservation, 4th edition, S.S. Block ed. , Lea and Febiger, (1991) .
  • the number of organisms surviving after exposure to a sterilization or killing treatment can be determined using equation 3.
  • N 0 is the initial number of viable spores or microorganisms and N is the number of surviving spores or microorganisms after exposure to a given sterilant dosage.
  • U is the total sterilant exposure time, e.g., total elapsed EtO exposure time or sterilant dosage.
  • D is a decimal reduction time, i.e., sterilant exposure required to kill one log of spores or cells.
  • D is a constant for a given set of conditions and batch or crop of spores or cells.
  • D is the negative reciprocal of the slope of a straight-line death curve.
  • a semilog plot of the observed LRV for a population of microbial spores versus sterilant exposure results in a negative-sloping line (sterilant exposure time/LRV response curve) .
  • This curve correlates to the straight-line death curve as shown in FIG. 2.
  • Adjusting the germination conditions such that the sterilant exposure time/LRV response curve is flatter indicates that the LRV response of a population of spores is less sensitive to sterilant exposure and visa versa.
  • a steep slope is preferred for biological indicators because it increases the sensitivity and accuracy of the biological indicator.
  • the "slope" is the absolute value of the slope of the sterilant exposure time/LRV response curve.
  • a steep slope is from about 0.014 to about 0.024.
  • the slope is from about 0.0185 to about 0.02.
  • the y- intercept, slope and coefficient of determination for sterilant exposure time/LRV response curves were computed using the computer program SigmaPlot (Jendel Scientific) .
  • a steepness index may be computed instead of determining the actual slope of the sterilant exposure time/LRV response curve. Using a steepness index is particularly useful when EtO is the sterilant.
  • the steepness index is the value obtained when the LRV response at 0 minutes of EtO exposure (y-intercept) is divided by the LRV response computed at 60 minutes of a standard EtO exposure cycle.
  • the germination media described herein may be optimized for the LRV response by adjusting the concentration of the individual ingredients so as to produce the steepest slope or largest slope index attainable for different spore types and/or different sterilants.
  • a standard EtO sterilization cycle employs conditions of about 60% relative humidity, EtO exposure at a concentration of 600 mg EtO/L of air at a temperature of about 55°C.
  • the ethylene oxide sterilization cycles used herein were conducted in a Joslyn Biological Indicator Evaluator Resistomer (B.I.E.R.) gas sterilizer.
  • the cycles included a 15 minute preheat at 55°C followed by a 30 minute dwell time at 60% relative humidity followed by an EtO sterilization dwell time at a concentration of 600 mg EtO/L of air at a temperature of about 55°C followed by 3 deep vacuum cycles, and a final 1 minute low vacuum aeration at 55 °C.
  • EtO exposure times refer to the length of the EtO sterilization dwell time only.
  • the preheat, humidity dwell, vacuum cycles, and low vacuum aeration were kept constant.
  • sterilant refers to a sterilizing agent used in any method of sterilization and includes, for example, steam, ethylene oxide, radiation, heat, sodium hypochlorite, polyvinylpyrrolidone- iodine, sodium dichlorocyanurate, low temperature steam-formaldehyde, glutaraldehyde, hydrogen peroxide, hydrogen peroxide plasma, peracetic acid and mixtures thereof.
  • spores must be dried onto a suitable carrier material in order to expose the spores to a sterilant.
  • the spores can be dried on any suitable carrier material such as paper, plastic, glass, metal or other nondispersible carrier.
  • a suitable carrier includes plastic or glass cuvettes.
  • the spores can be dried down in the presence of various additives that can alter a spore's sensitivity to sterilant exposure. Illustrative examples of additives and methods for applying additives are disclosed in United States Patent Application Serial No. 09/061,293. Drying the spores in the presence of additives is defined as pre-conditioning the spores.
  • the drying temperature is typically between about 45-50°C, preferably, between about 47-48°C.
  • a suspension of treated spores can be dried down in four hours at about 48°C. Spores dried in this manner appear dry on the surface, but likely retain residual amounts of bound water within the spore.
  • the spore suspension can be dried onto a carrier for about 12-20 hours at about 37°C. Typically, 12 hours or overnight drying is sufficient.
  • the invention features a defined spore germination medium (GM) that increases the LRV.
  • GM spore germination medium
  • the GM includes a base solution (GM-base) , at least one germinant and at least one effector.
  • the GM can also include a GM-base solution further containing a germinant, an effector, and/or a compound of unknown activity or any combination thereof.
  • the GM or GM-base can be unfiltered or filtered through a 0.2 ⁇ m sterile filter.
  • a filtered germination medium is designated by an "F" preceding the media designation, e.g., FGM or FGM- base .
  • a GM may or may not trigger spore germination whereas the GM-base solution will not trigger spore germination, i.e., the measured LRV is less than or equal to about 0.0008 Abs 480 /min.
  • baseline germination or no germination measured spectrophotometrically is an LRV ⁇ 0.0005 ⁇ 0.0003 Abs 480 /min.
  • Optimal Bacillus subtilis spore GM-base solutions can include the following constituents: (1) 0.01-0.2 M phosphate buffer (equal parts KH 2 P0 4 and Na 2 HP0 4 ) , pH 6.8-7.8 at 23°C;
  • GM-base solutions that were within the concentration ranges recited above, the disclosed methods are applicable to GM-base solutions lacking one or all of the constituents listed.
  • GM-base solutions lacking one or more of the described constituents can be useful for identifying germinants and effectors of non-GS-II mediated germination mechanisms and for optimizing the germination parameters of spores other than Bacillus subtilis .
  • Altering the phosphate concentration is useful for accommodating the sensitivity of different types of spores or different spore crops used in a biological indicator.
  • increasing the phosphate concentration in a FGM-base solution from about 0.01 to about 0.2 M phosphate concentration increased the slope (i.e., more negative) of the EtO exposure time/LRV response curve from about 0.0118 to about 0.0205, respectively.
  • Increasing the phosphate concentration in a FGM-base solution from about 0.01 to about 0.1 M phosphate increases in the y-intercept for a plot of the EtO exposure time/LRV response curve up to about 0.1 M phosphate.
  • Increasing the phosphate concentration above about 0.15 M causes an appreciable decrease in the y- intercept .
  • a preferred Bacillus subtilis spore GM-base solution includes: (1) 0.1 M phosphate buffer (6.95 g/L KH 2 P0 4 + 6.95 g/L Na 2 HP0 4 ) , pH 7.25 at 22 °C;
  • Another preferred GM-base solution includes constituents 1-5 from above wherein the phosphate buffer is at a concentration of about 0.15 M.
  • Other buffers including the zwitterion buffers such as ACES, HEPES , MOPS, PIPES and TRIZMA buffers can be used in GM-base solutions.
  • the LRV response measured for spores germinated in GMs containing buffers other than phosphate is less responsive and thus phosphate is preferred for GMs used in biological indicators.
  • the effects of MgS0 4 , CaCl 2 and urea have been evaluated. Other than urea, which reduced the observed lag period for spore germination by up to 1 minute, there does not appear to be any benefit to adding such compounds.
  • germinants trigger spore germination to a significant extent when added to a GM- base solution, i.e., LRV > 0.008 Abs 480 /min. Effectors cause a synergistic increase in the LRV when added to a GM containing a germinant and cause a concomitant decrease in the K ⁇ of the germinant.
  • Germinants and effectors include the tested compounds and operable derivatives thereof.
  • an operable derivative is a derivative of a germinant or effector that when tested using the methods disclosed herein continues to function as a germinant, effector or both.
  • a compound can be both a germinant and an effector, e.g., L-Thr.
  • Useful germinants include the compounds listed in Table 1.
  • the concentration ranges listed in Table 1 are the ranges that triggered Bacillus subtilis spore (initial Abs 480 normalized to 0.5) germination in FGM from barely above the background (LRV « 0.001 Abs 480 /min) to about the observed maximum for each germinant .
  • L-alanine (L-Ala) 0.0003-1 mg/ml
  • L-o.-amino butyric acid (L- ⁇ ..Abu) 0.001-1 mg/ml
  • L-cysteine 0.03-3 mg/ml
  • L-valine 0.03-30 mg/ml
  • L-isoleucine (L-Ile) 0.1-10 mg/ml
  • ⁇ -alanine ( ⁇ -Ala) 0.2-10 mg/ml
  • L-homoserine (L-hSer) 0.3-30 mg/ml
  • L-leucine (L-Leu) 1-30 mg/ml
  • L-allothreonine (L-aThr) 1-30 mg/ml
  • preferred effectors are those compounds that, in combination with identified germinants such as L-Ala or L-Val, gave the steepest EtO exposure time/LRV response curves.
  • Preferred effectors include L- Gin and L-Asn used at concentrations from about 0.3 g/L to about 10 g/L. Synergy can be measured at L-Asn or L- Gln concentrations as low as 0.1 mg/ml, but neither the LRV nor the EtO exposure time/LRV response is useful in biological indicators at concentrations below about 1 mg/ml .
  • Illustrative examples of useful GMs containing both germinants and effectors include GMs containing the germinant L-Val at a concentration from about 0.1 g/L to about 1.0 g/L or the germinant L-Ala from about 1.0 mg/L to about 10 mg/L and further containing the effector L- Gln at a concentration from about 1 g/L to about 10 g/L or the effector L-Asn at a concentration from about 1 g/L to about 10 g/L.
  • a preferred GM includes a preferred FGM-base solution containing 0.15 M phosphate buffer (pH 7-7.4) additionally containing L-Val at a concentration from about 0.1 g/L to about 0.3 g/L and L-Gln at a concentration from about 3 g/L to about 8 g/L.
  • a more preferred GM includes the preferred FGM-base solution additionally containing L-Val at a concentration of about 0.1 g/L (0.85 mM) and L-Gln at a concentration of about 5 g/L (34.2 mM) .
  • L-Ala at a concentration from about 1 mg/L to about 4 mg/L, preferably 1 mg/L, can be substituted for L-Val.
  • L-Asn at a concentration of about 3 g/L can be substituted for L-Gln, but the slope of the EtO exposure time/LRV response curve is not as steep.
  • RV measured for GM containing L-Ala at a concentration of 0.006 mg/ml.
  • Tables 5 and 6 depict the K influence computed for the germinant L-Ala in the presence or absence of effectors or borderline effectors in Tables 2 and 3, respectively.
  • GS-II is shown to be more sensitive to EtO than either GS-I or GS-III. Since GS-II is sensitive to EtO, it is preferable to trigger the GS-II mechanism as opposed to the GS-I or GS- III mechanism for biological indicators used in EtO sterilizers. Further, the discovery of cooperativity between effector molecules and germinants facilitates the manipulation of the germinant and effector concentrations in a GM in order to alter the correspondence between spore germination rates and sterilant exposure time.
  • the invention will be further understood with reference to the following illustrative embodiments, which are purely exemplary, and should not be taken as limiting the true scope of the present invention as described in the claims. Unless otherwise indicated, each example used commercial lots of L-Asn or L-Gln that were substantially free of other germination active contaminants .
  • This example illustrates the difference in germination activity levels observed for commercial lots of L-Gln and L-Asn.
  • Commercial lots of L-Gln and L-Asn were purchased from Sigma Chemical Company (Lot# 15F-0680 & 89F-0398) or Aldrich Chemical Company (Lot# 06710EV & 03220PN) , respectively.
  • FGM containing FGM-base solution (1.67 mM fructose, 1.67 mM glucose, 0.2 M KCl, 0.1 M NaCl and 0.1 M phosphate buffer (6.95 g KH 2 P0 4 /L + 6.95 g Na 2 HP0 4 /L, pH 7.25 at 22°C) ) and the appropriate concentration of germinant and/or effector were added to each cuvette to initiate germination.
  • the appropriate concentrations of L-Ala (Aldrich Lot# AF06311PZ) , L-Gln, and/or L-Asn are indicated in Table 7.
  • FGMs containing L-Asn or L-Gln were used to trigger Bacillus subtilis spore germination in the presence or absence of L-Ala.
  • the L-Ala concentrations were below saturating concentrations.
  • L-Ala (0.001) 0.008 10.2 L-Ala (0.003) 0.017 2.9 L-Ala (0.01) 0.026 3.0 L-Ala (0.03) 0.035 2.8
  • L-Ala (0.001) L-Asn (10) 03220PN 0.027 3.6 L-Ala (0.003) L-Asn (10) 03220PN 0.037 2.3 L-Ala (0.01) L-Asn (10) 03220PN 0.041 1.1 L-Ala (0.03) L-Asn (10) 03220PN 0.042 5.6 L-Ala (0.001) 0.007 8.3 L-Ala (0.003) 0.017 2.2 L-Ala (0.01) 0.026 4.0 L-Ala (0.03) 0.034 1.8
  • L-Ala (0.001) L-Gln (6) 89F-0398 0.031 1.1 L-Ala (0.003) L-Gln (6) 89F-0398 0.040 1.0 L-Ala (0.01) L-Gln (6) 89F-0398 0.042 1.5 L-Ala (0.03) L-Gln (6) 89F-0398 0.044 3.5 L-Ala added to FGMs containing inactive L-Asn (lot#
  • the LRV for active L-Asn (lot# 06710EV) was approximately equal to the LRV computed for inactive L-Asn combined with L-Ala at a concentration of 0.001 mg/ml.
  • L-Ala concentration increased the LRV to a maximum of 0.042 at an L-Ala concentration of 0.03 mg/ml.
  • the LRV computed for the active lot of L-Gln (lot# 15F- 0680) was equivalent to the LRV computed for 0.01 mg/ml L-Ala added to the inactive lot of L-Gln.
  • inactive L-Gln (lot# 89F-0398) was combined with L-Ala, the LRV reached a plateau at an L-Ala concentration between 0.003-0.006 mg/ml, which suggested that the active lot of L-Gln contained at least 0.06% L-Ala.
  • LRVs were computed in FGMs prepared according to the procedures described in Example 1. Each unknown compound was used to compute an LRV alone, combined with L-Ala, and combined with L-Gln. The results are shown in Table 8. The LRV computed for the FGM-base solution was ⁇ 0.001 ABS 480 /min. TABLE 8 Identifying Synergy Between Compounds of Unknown Spore
  • the L-Ala concentrat on was fixed in the FGM at 0.006 mg/ml .
  • LRV G L-Ala at a concentration of 0.006 mg/ml (LRV 0.0232 Abs 480 /min) (see row 2 of this table).
  • L- Asn, L-Gln some compounds (e.g., L- Asn, L-Gln) are weaker germinants than others (e.g., L- Ala and L-Val) .
  • the LRV of the L-Gln or L-Asn may have been due to trace contaminations of a germination active compound, most likely L-Ala at a concentration below about 0.3 ⁇ g/ml. Using this method any compound or an operable derivative thereof can be identified as a germinant or an effector candidate.
  • Example 3 Concentration Dependence of Synergistic Interactions This example illustrates a method for computing changes in the Kache for germinants in the presence of effector compounds or effector candidate compounds.
  • FGMs were prepared according to the procedures described in Example 1. The concentration of the germinant L-Ala or L-Val was increased as indicated in Table 9 to create a saturation kinetics curve. LRVs including standard deviations (%SD) were computed.
  • the LRV response for FGMs containing both germinant and effector was saturated at about 0.01 mg/ml for L-Ala (0.112 mM) and at about 1.0 mg/ml for L-Val (8.54 mM) , well below the saturating concentration for either of the germinants in the absence of the effectors.
  • Ala was biphasic indicating that L-Ala bound to more than one receptor with different affinities. Therefore, two K ⁇ values were computed: L-Ala (L) (0.001-0.01 mg/ml) and L-
  • Val was monophasic.
  • L-Val did not trigger spore germination at concentrations as low as L-Ala preventing K circumstances determinations for L-Val below 0.1 mg/ml.
  • both L-Asn and L-Gln substantially reduced the K tendency for L-Ala and L-Val triggered germination.
  • the synergistic effect observed for L-Ala (L) was approximately twice that observed for L-Val.
  • FGM FGM containing 1.67 mM fructose, 1.67 mM glucose, 0.2 M KCl, 0.1 M NaCl and 0.1 M phosphate buffer (6.95 g KH 2 P0 4 /L + 6.95 g Na 2 HP0 4 /L, pH 7.25 at 22°C) was added to each cuvette.
  • the FGM also included the appropriate concentration of a germinant and/or effector as indicated in Table 11.
  • the slope values for the EtO exposure time/LRV response curves for spore germination triggered with L-Ala at a concentration of 0.001, 0.01, and 0.1 mg/ml in the presence of L-Gln were 0.0177, 0.014, and 0.0087, respectively .
  • Increasing the L-Ala concentration in the FGM containing either L-Asn or L-Gln decreased the slope of the EtO exposure time/LRV response curve.
  • Increasing the L-Ala concentration lowered the sensitivity of the LRV response, which is likely due to L-Ala triggering a non-GSII spore germination mechanism.
  • Germinant Effector Mean LRV (mg/ml) (mg/ml) (Min) %SD s 2 L-Ala (0.0006) 0.024 2. ,0 - L-Thr (5.0) 0.005 6. .3 - L-Thr (7.5) 0.014 2. .3 - L-Thr (10) 0.024 5, .4 - L-Thr (15) 0.038 0, .7 - L-Thr (20) 0.042 1. .3 -
  • L-Thr was synergistic with L-Ala at concentrations below 7.5 mg/ml. Additionally, unlike L-Asn and L-Gln, L-Thr itself triggered spore germination. L-Thr may constitute a compound that is capable of homotropic positive cooperativity .
  • L-aThr triggered spore germination.
  • Additional experiments using the procedures described in Example 3 were conducted to determine if L- aThr altered the binding efficiency of L-Ala.
  • L-Ala was varied from 0.001 mg/ml to 0.009 mg/ml in the presence or absence of L-aThr at a concentration of 5.0 mg/ml.
  • L-aThr was anomalous in that its S 2 values indicated that L-aThr was not synergistic with L-Ala and yet the K influence ratio indicated a significant synergistic interaction. It is possible that L-aThr is anomalous because its germinant characteristics dominated over its effector characteristics .
  • Example 6 Synergistic Interactions Between L-Cvs and L-Ala Experimental procedures as described in Examples 1 and 2 were used to compute LRVs for L-Cys and L-Ser with L- Ala. The results are shown in Table 13.
  • L-Cys was not synerg:istic wi ,th L-Ala.
  • An S 2 ⁇ 1 indicated an antagonistic effect similar to the effects observed for other germinants that were also not synergistic with L-Ala (see Table 8) .
  • L-Cys did trigger spore germination with relatively high germination rates.
  • L-Gln and L-Asn would be synergistic with L-Cys.
  • L-Ser was synergistic with L-Ala.
  • L-Ser and L-Ala became antagonistic, similar to the response observed for L-Thr (Example 5) .
  • L-Ser was a borderline effector candidate .
  • Example 7 Effect of GM Composition on the LRV Response
  • FPO is the standard medium used for activating only GS-I mediated spore germination in the presence of a germinant.
  • GS-I and GS-III mediated germination are activated when an FGM contains a germinant.
  • GS-II mediated germination is activated when the FGM contains both a germinant and an effector. Only the GS-II mediated germination, however, is sensitive enough to EtO sterilization to be useful for monitoring the effectiveness of an EtO sterilization process.
  • FGM-base solution containing 1.67 mM fructose, 1.67 mM glucose, 0.2 M KCl, 0.1 M NaCl and 0.1 M phosphate buffer (6.95 g KH 2 P0 4 /L + 6.95 g Na 2 HP0 4 /L, pH 7.25 at 22°C) was combined with L-Ala at concentrations indicated in Table 14. Each germination reaction was repeated in the presence or absence of the effector L-Gln at a concentration of 3 mg/ml . The experimental procedures were repeated using an FGM-base solution containing only filtered 50 mM phosphate (FPO-base) . The results are shown in Table 14
  • Example 4 Experimental procedures described in Example 4 were followed in order to compare the y-intercept and slope of the EtO exposure time/LRV response curve for the combination of L-Gln and L-Val in either an FGM-base solution containing 1.67 mM fructose, 1.67 mM glucose, 0.2 M KCl, 0.1 M NaCl and 0.1 M phosphate buffer (6.95 g KH 2 P0 4 /L + 6.95 g Na 2 HP0 4 /L, pH 7.25 at 22°C) or in filtered 50 mM phosphate buffer (FPO) consisting of equal parts Na 2 HP0 4 and KH 2 P0 4 .
  • FPO mM phosphate buffer
  • FPO L-Ala (0.01) 0. .0149 0. ,0066 0. .99 FPO L-Ala (0.10) 0. .0171 0. .0056 0. .98 FPO L-Val (0.1) 0. .0003 0. .0000 -- FPO L-Ala (0.01) /L-Gln (3.0) 00.. .00119922 0, .0079 1. .00 FGM L-Val (0.1) 0, .0060 0, .0106 1. .00 FGM L-Val (0.1) /L-Gln (3.0) 0, .0349 0, .0177 1.
  • LRV G 0.0360 A s 480 m n L-A a 0.006 mg m .
  • 2 LRV G 0.0370 Abs 480 /min (L-Ala 0.006 mg/ml) .
  • 3 LRV G 0.0381 Abs 480 /min (L-Ala 0.006 mg/ml) ; Table 17 K flesh Ratios
  • Effector mg/ml Alone (a) Effector (b) a/b D-Asn 10.0 0.0129 0.0035 3.7
  • D-Asn and D-Gln were synergistic with L-Ala while D-Thr was antagonistic. These results confirmed that L-Thr is both an effector and a germinant. Further, these results confirm that L-Asn and L-Gln are only effector molecules and do not act as germinants because the D-isomers did not inhibit L-Ala triggered germination and did not trigger germination when used alone. The results for D- Asn and D-Gln were very unexpected because it is generally thought that the D-amino acids act as competitive inhibitors for known germinants. The observed lack of germination inhibition by D-Asn and D- Gln, however, suggests that the binding sites for effectors and germinants are distinct.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un milieu de germination de spores améliorant le taux de germination des spores, comprenant un germinant et un effecteur interagissant avec synergie. Lesdits germinant et effecteur peuvent comprendre des acides aminés, tels que Ala, Val, Asn et Gln. La germination des spores déclenchée par le milieu de germination de cette invention peut être utilisé pour calculer et évaluer la survie des spores après leur exposition à un stérilisant.
PCT/US1998/015612 1997-07-28 1998-07-28 Milieu de germination de spores Ceased WO1999005310A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000504279A JP2001511356A (ja) 1997-07-28 1998-07-28 胞子発芽培地
AU85970/98A AU8597098A (en) 1997-07-28 1998-07-28 Spore germination media

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5395897P 1997-07-28 1997-07-28
US60/053,958 1997-07-28

Publications (1)

Publication Number Publication Date
WO1999005310A1 true WO1999005310A1 (fr) 1999-02-04

Family

ID=21987731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015612 Ceased WO1999005310A1 (fr) 1997-07-28 1998-07-28 Milieu de germination de spores

Country Status (3)

Country Link
JP (1) JP2001511356A (fr)
AU (1) AU8597098A (fr)
WO (1) WO1999005310A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002113486A (ja) * 2000-10-06 2002-04-16 Mitsui Eng & Shipbuild Co Ltd 有機性廃水の処理方法及び処理装置
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
EP2145948A1 (fr) * 2009-03-09 2010-01-20 Biotecnologie BT S.r.l. Compositions adaptées pour la botrytisation
US8628953B2 (en) 2007-11-29 2014-01-14 Hitachi Plant Technologies, Ltd. Capturing carrier, capturing device, analysis system using the same, and method for capturing and testing microorganisms
WO2014124120A1 (fr) * 2013-02-06 2014-08-14 Envera, Llc Mélanges séchés de composés germinatifs et de spores
WO2014193746A1 (fr) * 2013-05-31 2014-12-04 Novozymes Bioag A/S Compositions et procédés pour l'activation de la germination
US9499774B2 (en) 2012-02-17 2016-11-22 The Clorox Company Targeted performance of hypohalite methods thereof
WO2017176872A1 (fr) * 2016-04-05 2017-10-12 Nch Corporation Composition d'agent de germination riche en nutriment et procédé d'incubation de spores
EP3177149A4 (fr) * 2014-08-06 2017-12-20 Envera LLC Compositions de spores bactériennes à usages industriels
WO2018009335A1 (fr) * 2016-07-08 2018-01-11 Novozymes Bioag A/S Ajout séquentiel de germinants moléculaires à des spores bactériennes
WO2018026446A1 (fr) * 2016-07-30 2018-02-08 Novozymes Bioag A/S Composition comprenant des non-germinants et des spores bactériennes
WO2020136613A1 (fr) 2018-12-27 2020-07-02 3M Innovative Properties Company Indicateur biologique de lecture instantanée avec confirmation de croissance
US10766799B2 (en) * 2014-05-23 2020-09-08 Nch Corporation Method for improving quality of aquaculture pond water using a nutrient germinant composition and spore incubation method
CN111808787A (zh) * 2020-08-12 2020-10-23 河南农业大学 一种提高生孢梭菌芽孢萌发率的方法
US10897922B2 (en) 2016-04-05 2021-01-26 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
CN112601453A (zh) * 2018-08-29 2021-04-02 Nch公司 用于温育在水产养殖、农业、废水和环境修复应用中使用的孢子的系统、方法和组合物
CN112941006A (zh) * 2021-02-07 2021-06-11 广东省科学院生物工程研究所 一种稻瘟病菌孢子的制备方法
US20210205377A1 (en) * 2016-04-05 2021-07-08 Nch Corporation System and Method for Using a Single-Serve Nutrient Spore Composition for Small Scale Farm Applications
WO2022034498A1 (fr) 2020-08-12 2022-02-17 3M Innovative Properties Company Dispositifs de surveillance de stérilisation à front mobile
US11576937B2 (en) 2020-02-06 2023-02-14 Nch Corporation Method of reducing gut inflammation reduction in humans by consuming a heated probiotic composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4634725B2 (ja) * 2004-02-12 2011-02-16 マツモト総合企画有限会社 有機物を分解する微生物用の活性化剤
JP2007195542A (ja) * 2005-12-27 2007-08-09 Kumiai Chem Ind Co Ltd 微生物農薬の調製に適したバシルス属細菌の胞子の製造方法
JP2016182086A (ja) * 2015-03-26 2016-10-20 公益財団法人東洋食品研究所 容器詰め食品の製造方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126325A (en) * 1964-03-24 Kzhpox
US3687815A (en) * 1970-01-30 1972-08-29 Monsanto Co Germination of spores
JPS4911425B1 (fr) * 1970-12-23 1974-03-16
JPS5338643A (en) * 1976-09-22 1978-04-08 Hayashikane Sangyo Method of producing sealeddup food
US4311793A (en) * 1978-04-20 1982-01-19 Halleck Frank E Sterilization indicator
WO1995021936A1 (fr) * 1994-02-15 1995-08-17 Minnesota Mining And Manufacturing Company Indicateur biologique a lecture rapide
US5614375A (en) * 1994-03-23 1997-03-25 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Method and test kit for the rapid detection of biotoxic contaminants

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126325A (en) * 1964-03-24 Kzhpox
US3687815A (en) * 1970-01-30 1972-08-29 Monsanto Co Germination of spores
JPS4911425B1 (fr) * 1970-12-23 1974-03-16
JPS5338643A (en) * 1976-09-22 1978-04-08 Hayashikane Sangyo Method of producing sealeddup food
US4311793A (en) * 1978-04-20 1982-01-19 Halleck Frank E Sterilization indicator
WO1995021936A1 (fr) * 1994-02-15 1995-08-17 Minnesota Mining And Manufacturing Company Indicateur biologique a lecture rapide
US5614375A (en) * 1994-03-23 1997-03-25 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Method and test kit for the rapid detection of biotoxic contaminants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 74-28165V, XP002085171 *
DATABASE WPI Derwent World Patents Index; AN 78-35968A, XP002085170 *

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
JP2002113486A (ja) * 2000-10-06 2002-04-16 Mitsui Eng & Shipbuild Co Ltd 有機性廃水の処理方法及び処理装置
US8628953B2 (en) 2007-11-29 2014-01-14 Hitachi Plant Technologies, Ltd. Capturing carrier, capturing device, analysis system using the same, and method for capturing and testing microorganisms
WO2010102768A3 (fr) * 2009-03-09 2010-11-25 Biotecnologie Bt S.R.L. Compositions appropriées pour une botrytisation
EP2145948A1 (fr) * 2009-03-09 2010-01-20 Biotecnologie BT S.r.l. Compositions adaptées pour la botrytisation
US10066193B2 (en) 2012-02-17 2018-09-04 The Clorox Company Targeted performance of hypohalite methods thereof
US9499774B2 (en) 2012-02-17 2016-11-22 The Clorox Company Targeted performance of hypohalite methods thereof
WO2014124120A1 (fr) * 2013-02-06 2014-08-14 Envera, Llc Mélanges séchés de composés germinatifs et de spores
KR102302522B1 (ko) 2013-02-06 2021-09-14 엔베라 엘아이씨, 엘엘씨 건조된 포자 발아성 화합물 혼합물
KR20150133699A (ko) * 2013-02-06 2015-11-30 엔베라, 엘엘씨 건조된 포자 발아성 화합물 혼합물
CN105121622A (zh) * 2013-02-06 2015-12-02 恩威拉有限责任公司 干燥的孢子萌发化合物混合物
US9447376B2 (en) 2013-02-06 2016-09-20 Envera, Llc Dried spore germinative compound mixtures
EA034962B1 (ru) * 2013-02-06 2020-04-13 Инвира Элайси, Ллс Высушенные смеси со способствующими прорастанию спор соединениями
AU2014214917B2 (en) * 2013-02-06 2019-09-26 Envera Lic, Llc Dried spore germinative compound mixtures
US10308909B2 (en) 2013-02-06 2019-06-04 Envera Lic, Llc Dried spore germinative compound mixtures
CN105764344A (zh) * 2013-05-31 2016-07-13 诺维信生物农业公司 用于增强萌发的组合物和方法
EP3003049A4 (fr) * 2013-05-31 2016-12-07 Novozymes Bio Ag As Compositions et procédés pour l'activation de la germination
WO2014193746A1 (fr) * 2013-05-31 2014-12-04 Novozymes Bioag A/S Compositions et procédés pour l'activation de la germination
US10766799B2 (en) * 2014-05-23 2020-09-08 Nch Corporation Method for improving quality of aquaculture pond water using a nutrient germinant composition and spore incubation method
US9932543B2 (en) 2014-08-06 2018-04-03 Envera, Llc Bacterial spore compositions for industrial uses
EP3177149A4 (fr) * 2014-08-06 2017-12-20 Envera LLC Compositions de spores bactériennes à usages industriels
US10897922B2 (en) 2016-04-05 2021-01-26 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
US20210205377A1 (en) * 2016-04-05 2021-07-08 Nch Corporation System and Method for Using a Single-Serve Nutrient Spore Composition for Small Scale Farm Applications
US12097226B2 (en) 2016-04-05 2024-09-24 Nch Corporation System and method for using a single-serve nutrient spore composition for small scale farm applications
WO2017176872A1 (fr) * 2016-04-05 2017-10-12 Nch Corporation Composition d'agent de germination riche en nutriment et procédé d'incubation de spores
US11805800B2 (en) 2016-04-05 2023-11-07 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
US11484556B2 (en) 2016-04-05 2022-11-01 Nch Corporation Nutrient rich germinant composition and spore incubation method
US11206860B2 (en) 2016-04-05 2021-12-28 Nch Corporation Composition and method for germinative compounds in probiotic food and beverage products for human consumption
US10610552B2 (en) 2016-04-05 2020-04-07 Nch Corporation Nutrient rich germinant composition and spore incubation method
WO2018009335A1 (fr) * 2016-07-08 2018-01-11 Novozymes Bioag A/S Ajout séquentiel de germinants moléculaires à des spores bactériennes
WO2018026446A1 (fr) * 2016-07-30 2018-02-08 Novozymes Bioag A/S Composition comprenant des non-germinants et des spores bactériennes
CN112601453A (zh) * 2018-08-29 2021-04-02 Nch公司 用于温育在水产养殖、农业、废水和环境修复应用中使用的孢子的系统、方法和组合物
US11401500B2 (en) 2018-08-29 2022-08-02 Nch Corporation System, method, and composition for incubating spores for use in aquaculture, agriculture, wastewater, and environmental remediation applications
WO2020136613A1 (fr) 2018-12-27 2020-07-02 3M Innovative Properties Company Indicateur biologique de lecture instantanée avec confirmation de croissance
US11576937B2 (en) 2020-02-06 2023-02-14 Nch Corporation Method of reducing gut inflammation reduction in humans by consuming a heated probiotic composition
WO2022034498A1 (fr) 2020-08-12 2022-02-17 3M Innovative Properties Company Dispositifs de surveillance de stérilisation à front mobile
CN111808787A (zh) * 2020-08-12 2020-10-23 河南农业大学 一种提高生孢梭菌芽孢萌发率的方法
CN112941006A (zh) * 2021-02-07 2021-06-11 广东省科学院生物工程研究所 一种稻瘟病菌孢子的制备方法

Also Published As

Publication number Publication date
JP2001511356A (ja) 2001-08-14
AU8597098A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
WO1999005310A1 (fr) Milieu de germination de spores
US5795730A (en) Rapid read-out biological indicator
US8043845B2 (en) Sterilization indicator
US6187555B1 (en) Spores with increased sensitivity to sterilants using additives that bind to sterilant-sensitive sites
KR20100118995A (ko) 안정한 조효소를 사용하는 탈수소효소의 안정화
EP0745138B1 (fr) Indicateur de sterilisation biologique a lecture rapide
ES2148125T3 (es) Procedimiento de regulacion de la desinfeccion de liquidos.
Okada et al. Chloramphenicol is an inhibitor of photosynthesis
Waites et al. Germination of spores of Clostridium bifermentans by certain amino acids, lactate and pyruvate in the presence of sodium or potassium ions
JP3856467B2 (ja) 微生物学的試験方法および試薬
US20200063178A1 (en) Biological indicator
Nitta et al. L-amino acid dehydrogenases in Bacillus subtilis spores
Tischler et al. Factors involved in in vitro stabilization of nitrate reductase from cotton (Gossypium hirsutum L.) cotyledons
Fikes et al. Studies on the mode of action of a bacteriocin produced by Bacillus stearothermophilus
Dadd et al. Germination of spores of Bacillus subtilis var. niger following exposure to gaseous ethylene oxide
Friedberg et al. The Protection of Alpha-Chymotrypsin by Hydrocinnamate from Denaturation by Ethanol and Urea
Sotomayor et al. Influence of gamma irradiation on a natural source of peroxidase and its effect in the reagentless amperometric biosensor for hydrogen peroxide
JP3078343B2 (ja) 測定用組成物
Ye et al. Inhibition of photosynthetic reactions by aureomycin
Kretschmer et al. Autolysis of Thermoactinomyces vulgaris spores lacking carbon dioxide during germination
TU et al. ADENOSINE TRIPHOSPHATE ENHANCES THE FLUORESCENCE OF 4′, 6‐DIAMIDINO‐2‐PHENYLINDOLE (DAPI)‐LABELED ESCHERICHIA COLI O157: H7 1
Arita A study of carboxypeptidase in Candida albicans during morphogenesis
FREY JR THE EFFECTS OF IRRADIATED MEDIUM ON SOME CELLULAR FUNCTIONS OF ESCHERICHIA COLI
MXPA00002609A (es) Procedimiento de regulacion de la desinfeccion de liquidos
WO2004033714A1 (fr) Identification et modulation d'intermediaires du metabolisme de l'alcool

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998937201

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998937201

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA